BACKGROUND: Although cardiopulmonary exercise (CPX) testing in patients with heart failure and reduced ejection fraction is well established, there are limited data on the value of CPX variables in patients with HF and preserved ejection fraction (HFpEF). We sought to determine the prognostic value of select CPX measures in patients with HFpEF. METHODS: This was a retrospective analysis of patients with HFpEF (ejection fraction ≥ 50%) who performed a CPX test between 1997 and 2010. Selected CPX variables included peak oxygen uptake (VO2), percent predicted maximum oxygen uptake (ppMVO2), minute ventilation to carbon dioxide production slope (VE/VCO2 slope) and exercise oscillatory ventilation (EOV). Separate Cox regression analyses were performed to assess the relationship between each CPX variable and a composite outcome of all-cause mortality or cardiac transplant. RESULTS: We identified 173 HFpEF patients (45% women, 58% non-white, age 54 ± 14 years) with complete CPX data. During a median follow-up of 5.2 years, there were 42 deaths and 5 cardiac transplants. The 1-, 3-, and 5-year cumulative event-free survival was 96%, 90%, and 82%, respectively. Based on the Wald statistic from the Cox regression analyses adjusted for age, sex, and β-blockade therapy, ppMVO2 was the strongest predictor of the end point (Wald χ(2) = 15.0, hazard ratio per 10%, P < .001), followed by peak VO2 (Wald χ(2) = 11.8, P = .001). VE/VCO2 slope (Wald χ(2)= 0.4, P = .54) and EOV (Wald χ(2) = 0.15, P = .70) had no significant association to the composite outcome. CONCLUSION: These data support the prognostic utility of peak VO2 and ppMVO2 in patients with HFpEF. Additional studies are needed to define optimal cut points to identify low- and high-risk patients.
BACKGROUND: Although cardiopulmonary exercise (CPX) testing in patients with heart failure and reduced ejection fraction is well established, there are limited data on the value of CPX variables in patients with HF and preserved ejection fraction (HFpEF). We sought to determine the prognostic value of select CPX measures in patients with HFpEF. METHODS: This was a retrospective analysis of patients with HFpEF (ejection fraction ≥ 50%) who performed a CPX test between 1997 and 2010. Selected CPX variables included peak oxygen uptake (VO2), percent predicted maximum oxygen uptake (ppMVO2), minute ventilation to carbon dioxide production slope (VE/VCO2 slope) and exercise oscillatory ventilation (EOV). Separate Cox regression analyses were performed to assess the relationship between each CPX variable and a composite outcome of all-cause mortality or cardiac transplant. RESULTS: We identified 173 HFpEF patients (45% women, 58% non-white, age 54 ± 14 years) with complete CPX data. During a median follow-up of 5.2 years, there were 42 deaths and 5 cardiac transplants. The 1-, 3-, and 5-year cumulative event-free survival was 96%, 90%, and 82%, respectively. Based on the Wald statistic from the Cox regression analyses adjusted for age, sex, and β-blockade therapy, ppMVO2 was the strongest predictor of the end point (Wald χ(2) = 15.0, hazard ratio per 10%, P < .001), followed by peak VO2 (Wald χ(2) = 11.8, P = .001). VE/VCO2 slope (Wald χ(2)= 0.4, P = .54) and EOV (Wald χ(2) = 0.15, P = .70) had no significant association to the composite outcome. CONCLUSION: These data support the prognostic utility of peak VO2 and ppMVO2 in patients with HFpEF. Additional studies are needed to define optimal cut points to identify low- and high-risk patients.
Authors: Raymond J Gibbons; Gary J Balady; J Timothy Bricker; Bernard R Chaitman; Gerald F Fletcher; Victor F Froelicher; Daniel B Mark; Ben D McCallister; Aryan N Mooss; Michael G O'Reilly; William L Winters; Raymond J Gibbons; Elliott M Antman; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Richard O Russell; Sidney C Smith Journal: J Am Coll Cardiol Date: 2002-10-16 Impact factor: 24.094
Authors: Gary J Balady; Ross Arena; Kathy Sietsema; Jonathan Myers; Lola Coke; Gerald F Fletcher; Daniel Forman; Barry Franklin; Marco Guazzi; Martha Gulati; Steven J Keteyian; Carl J Lavie; Richard Macko; Donna Mancini; Richard V Milani Journal: Circulation Date: 2010-06-28 Impact factor: 29.690
Authors: Sharon Ann Hunt; William T Abraham; Marshall H Chin; Arthur M Feldman; Gary S Francis; Theodore G Ganiats; Mariell Jessup; Marvin A Konstam; Donna M Mancini; Keith Michl; John A Oates; Peter S Rahko; Marc A Silver; Lynne Warner Stevenson; Clyde W Yancy Journal: Circulation Date: 2009-03-26 Impact factor: 29.690
Authors: Marco Guazzi; Jonathan Myers; Mary Ann Peberdy; Daniel Bensimhon; Paul Chase; Ross Arena Journal: Eur Heart J Date: 2008-10-04 Impact factor: 29.983
Authors: Marco Guazzi; Volker Adams; Viviane Conraads; Martin Halle; Alessandro Mezzani; Luc Vanhees; Ross Arena; Gerald F Fletcher; Daniel E Forman; Dalane W Kitzman; Carl J Lavie; Jonathan Myers Journal: Circulation Date: 2012-09-05 Impact factor: 29.690
Authors: Justin McNair Canada; Antonio Abbate; Rebecca Collen; Hayley Billingsley; Leo Francis Buckley; Salvatore Carbone; Cory Ross Trankle; Michael Ola Idowu; Dinesh Kadariya; Benjamin Van Tassell; Arun Jayant Sanyal; Mohammad Shadab Siddiqui Journal: Am J Cardiol Date: 2018-11-06 Impact factor: 2.778
Authors: Erik H Van Iterson; Thomas P Olson; Barry A Borlaug; Bruce D Johnson; Eric M Snyder Journal: Med Sci Sports Exerc Date: 2017-09 Impact factor: 5.411
Authors: Andrew R Coggan; Seth R Broadstreet; Kiran Mahmood; Deana Mikhalkova; Michael Madigan; Indra Bole; Soo Park; Joshua L Leibowitz; Ana Kadkhodayan; Deepak P Thomas; Dakkota Thies; Linda R Peterson Journal: J Card Fail Date: 2017-09-12 Impact factor: 5.712
Authors: Daniel E Forman; Ross Arena; Rebecca Boxer; Mary A Dolansky; Janice J Eng; Jerome L Fleg; Mark Haykowsky; Arshad Jahangir; Leonard A Kaminsky; Dalane W Kitzman; Eldrin F Lewis; Jonathan Myers; Gordon R Reeves; Win-Kuang Shen Journal: Circulation Date: 2017-03-23 Impact factor: 29.690
Authors: Yogesh N V Reddy; Thomas P Olson; Masaru Obokata; Vojtech Melenovsky; Barry A Borlaug Journal: JACC Heart Fail Date: 2018-05-23 Impact factor: 12.035
Authors: Andrew J Stewart Coats; Daniel E Forman; Mark Haykowsky; Dalane W Kitzman; Amy McNeil; Tavis S Campbell; Ross Arena Journal: Nat Rev Cardiol Date: 2017-05-18 Impact factor: 32.419
Authors: Stephen J Greene; Robert J Mentz; Mona Fiuzat; Javed Butler; Scott D Solomon; Andrew P Ambrosy; Cyrus Mehta; John R Teerlink; Faiez Zannad; Christopher M O'Connor Journal: Circulation Date: 2018-09-04 Impact factor: 29.690
Authors: Nicholas E Houstis; Aaron S Eisman; Paul P Pappagianopoulos; Luke Wooster; Cole S Bailey; Peter D Wagner; Gregory D Lewis Journal: Circulation Date: 2017-10-09 Impact factor: 29.690